| Business Summary | | Cardima,
Inc.
designs,
,
develops,
manufactures
and
markets
minimally
invasive,
single-use,
microcatheter-based
systems
for
the
mapping
and
ablation
of
the
two
most
common
forms
of
cardiac
arrhythmias,
atrial
fibrillation
(AF)
and
ventricular
tachycardia
(VT).
Arrhythmias
are
abnormal
electrical
heart
rhythms
that
adversely
affect
the
mechanical
activities
of
the
heart
and
can
potentially
be
fatal.
The
Company
develops
microcatheter
systems
designed
to
provide
enhanced
access
to
arrhythmia-causing
tissue,
to
diagnose
the
arrhythmia
by
locating
its
origin
(mapping),
and
to
restore
normal
heart
rhythms
by
isolating
and
destroying
the
arrhythmia-causing
sites
(ablation),
using
radiofrequency
(RF)
energy. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cardima,
Inc.
designs,
develops,
manufactures
and
markets
minimally
invasive,
single-use,
microcatheter-based
systems
for
the
mapping
and
ablation
of
the
two
most
comnon
forms
of
cardiac
arrhythmias.
For
the
six
months
ended
6/30/01,
net
sales
fell
28%
to
$1
million.
Net
loss
fell
54%
to
$2.6
million.
Revenues
reflect
the
transitioning
from
a
direct
sales
force
to
that
of
using
distributors.
Lower
loss
reflects
a
gain
on
sale
of
intellectual
property. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Phillip Radlick, Ph.D., 63 Chairman | $326K | Gabriel Vegh, 61 Pres,
CEO, Director | 315K | William Wheeler, 54 Sr.
VP of Worldwide Sales and Marketing | 191K | Victor Barajas, 37 VP
of Operations | 144K | Ronald Bourquin, 50 VP
and CFO | 225K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|